Novo Nordisk ® iving Norditropin ® sales growth e leadership maintained easing competition 35.5% Continue frequent launches with new indications and device upgrades Device portfolio ordisk gaa 2021 Pfizer Feb 2021 Roche Sandoz Noonan syndrome, EU device upgrades Current launches 1 16 Towards 2022 1 30
Download PDF file